What is HC Wainwright’s Forecast for ACXP FY2029 Earnings?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) – Research analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Acurx Pharmaceuticals in a note issued to investors on Wednesday, March 19th. HC Wainwright analyst E. Arce forecasts that the company will post earnings of ($0.57) per share for the year. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($0.89) per share.

Acurx Pharmaceuticals Stock Up 1.1 %

Shares of NASDAQ ACXP opened at $0.42 on Thursday. Acurx Pharmaceuticals has a 52-week low of $0.40 and a 52-week high of $3.33. The firm has a fifty day moving average of $0.69 and a 200-day moving average of $1.24. The stock has a market capitalization of $9.33 million, a PE ratio of -0.39 and a beta of -1.71.

Acurx Pharmaceuticals (NASDAQ:ACXP) last announced its quarterly earnings data on Monday, March 17th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02.

Insider Buying and Selling

In other Acurx Pharmaceuticals news, CEO David P. Luci purchased 49,261 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was purchased at an average cost of $1.01 per share, with a total value of $49,753.61. Following the transaction, the chief executive officer now owns 1,097,458 shares in the company, valued at approximately $1,108,432.58. This trade represents a 4.70 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 29.60% of the stock is owned by corporate insiders.

Institutional Trading of Acurx Pharmaceuticals

A hedge fund recently raised its stake in Acurx Pharmaceuticals stock. Prospect Financial Services LLC boosted its position in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 11.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 329,076 shares of the company’s stock after buying an additional 34,001 shares during the quarter. Prospect Financial Services LLC owned 1.93% of Acurx Pharmaceuticals worth $268,000 at the end of the most recent quarter. 11.53% of the stock is owned by hedge funds and other institutional investors.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.